An overview of antiplatelet and antithrombotic drugs.
Verstraete
M
M
Dejana
E
E
Fuster
V
V
Lapetina
E
E
Moncada
S
S
Mustard
J F
JF
Tans
G
G
Vargaftig
B B
BB
D000244:Adenosine Diphosphate / Q000378:metabolism; D001095:Arachidonic Acids / Q000378:metabolism; D001161:Arteriosclerosis / Q000503:physiopathology; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D001808:Blood Vessels / Q000293:injuries / Q000503:physiopathology; D004727:Endothelium / Q000502:physiology; D011464:Epoprostenol / Q000502:physiology; D004903:Erythrocyte Aggregation / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D010741:Phospholipases A / Q000502:physiology; D010743:Phospholipids / Q000502:physiology; D010972:Platelet Activating Factor / Q000502:physiology; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011448:Prostaglandin Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D011453:Prostaglandins / Q000502:physiology; D011982:Receptors, Prostaglandin / Q000187:drug effects; D017482:Receptors, Thromboxane; D013917:Thrombin / Q000502:physiology; D013923:Thromboembolism / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D010738:Type C Phospholipases / Q000502:physiology
D001095:Arachidonic Acids; D005343:Fibrinolytic Agents; D010743:Phospholipids; D010972:Platelet Activating Factor; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D000244:Adenosine Diphosphate; D011464:Epoprostenol; D010741:Phospholipases A; D010738:Type C Phospholipases; D013917:Thrombin; D013930:Thromboxane-A Synthase